The CDC's new vaccine panel is reviewing childhood immunization schedule, including dose timing, ingredients and cumulative effects.

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

Though the vaccine’s sales rose consistently till 2022, it started witnessing sluggish sales from 2024. Sales of the vaccine ...

Pfizer’s PFE Abrysvo is approved for the prevention of RSV-associated LRTD in all individuals aged 60 years and above, ... the FDA approved MRNA’s mResvia for use in high-risk adults aged 18 ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

David Fairlamb, Chief Development Officer at SolasCure said: “Given the unmet medical need and the poor outcomes for patients with calciphylaxis, the FDA’s granting Fast Track Designation is a ...

Some experts are concerned about the FDA’s plans. They include Stephen Holland, a former health adviser to Congress. He noted that during the pandemic, many FDA staffers were reassigned in order to ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease.